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Background
Mild persistent asthma is one of four severity
level classifications used by the National Asthma
Education and Prevention Practice (NAEPP)
Guideline for the Diagnosis and Management of
Asthma.1 It is classified on the basis of clinical
symptoms before treatment.
Mild persistent
asthma is categorized on the basis of symptoms
occurring on greater than two days per week but
less than once daily or greater than two nights per
month as well as spirometry measures of forced
expiratory volume in one second (FEV1) or peak
expiratory flow (PEF) > 80% and PEF variability
of < 20%.2
Recommended long-term control treatment for
mild persistent asthma is daily low-dose inhaled
corticosteroids. Guideline-suggested alternative
treatments include daily cromolyn, leukotriene
modifiers, nedocromil, or sustained release
theophylline with serum levels maintained
between five to 15 mcg/mL. Quick relief therapy
with a short-acting, inhaled beta-2 bronchodilator
is recommended as needed.2
Because of the variability in frequency and
intensity of mild persistent asthma symptoms,
patients may not adhere to daily use of inhaled
corticosteroids
but
rather
use
them
intermittently.3,4

budesonide 200 mcg twice daily plus zafirlukast
placebo tablets twice daily. Seventy-six patients
received zafirlukast 20 mg tablets twice daily plus
a placebo inhaler (Turbuhaler) one puff twice
daily. The third group of 76 patients received
placebo zafirlukast tablets twice daily and a
placebo inhalation of one puff twice daily.
All three treatment groups received either
“open-label” inhaled budesonide 800 mcg twice
daily for ten days or oral prednisone (0.5mg/kg)
daily for five days if their asthma exacerbated.
Both the initial treatment phase prior to
randomization (run-in phase) and the after-study
treatment phase consisted of a ten to 14 day
period of therapy with oral prednisone (0.5
mg/kg/day), 800 mcg inhaled budesonide twice
daily, and zafirlukast 20 mg twice daily, plus asneeded inhaled albuterol (540 to 720 mcg) to
eliminate any causes of airway flow obstruction.
Participants were followed for one year.
Routine visits were conducted and study
parameters were recorded.
FEV1 treatment
adherence, asthma control (using a questionnaire),
medication side effects, and symptom-related
difficulties and days were measured, assessed, and
discussed. Daily diaries were kept by participants
during certain periods of the study. Peak flow and
other personal observations were recorded by the
subjects.

Citation
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Methods
In this multicenter, double-blind trial, 225
adult patients (18 to 65 years of age) with
physician-diagnosed asthma who met evidencebased mild persistent asthma criteria were
randomized to one of three treatment groups.
Seventy-three
patients
received
inhaled

Results
One hundred ninety-nine patients completed
the study.
Patients followed the prescribed
treatment regimens greater than 90% of the time.
This level of adherence to protocol was similar in
all groups.
The change in morning PEF, the primary study
outcome, was similar in all treatment groups. The
morning PEF value increases were 8.3% in the
daily budesonide group, 7.9% in the daily
zafirlukast group, and 7.1% in the intermittent
treatment group (P = 0.90) corresponding to an
More. . .
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approximate 7.8% increase (32 liters per minute).
Kaplan-Meier estimates of the time to a first
exacerbation of asthma were similar for all
treatment groups (P=0.39). Similarly, there was
no difference in multiple event exacerbations per
patient in all treatment groups (P=0.24).
Compared with the daily zafirlukast and
intermittent therapy groups, the daily budesonide
group showed the greatest improvements in the
secondary outcomes of pre-bronchodilator FEV1
(P=0.005), asthma control score (P<0.001), and
number of symptom-free days score (P=0.03).
The treatment groups did not differ in the
secondary outcome parameters of postbronchodilator FEV1 scores (P=0.29) or asthma
quality of life scores (P=0.18).

Author Conclusions
The authors concluded that it is possible to
treat chronic mild persistent asthma in adults with
short, intermittent courses of inhaled or oral
corticosteroids whenever asthma exacerbations
occur. They caution that longer and larger studies
will be needed before this treatment approach can
be recommended.

Commentary
As the authors suggest, this novel approach to
treating mild persistent asthma in adults will
require further validation before it can be accepted
as a treatment option. The reality of patient
adherence to daily inhaled corticosteroid use for
mild persistent asthma is doubtful. Patients with
mild persistent asthma may not experience
exacerbations on a daily basis or their symptoms
are so mild that they “forget” or do not use their
prescribed treatment. Some may be concerned
about the safety of using long-term inhaled
steroids or the cost of medication. Yet, as
demonstrated in this study, it is possible to treat
patients with mild persistent asthma with
intermittent inhaled or oral corticosteroids
[Evidence level A; high-quality RCT].3
This study was the first trial conducted by the
Asthma Clinical Research Network (ACRN)
which was established in 1993 by the Division of
Lung Diseases (DLD), and the National Heart,
Lung and Blood Institute (NHLBI). This study by
Boushen et al is entitled: IMProving Asthma
Control Trial (IMPACT).3,5

One of the questions concerning this trial
focuses on the cost associated with the daily use
of “controller” therapy in asthma. Using the
ACRN mild persistent asthma prevalence and cost
assumptions, daily inhaled corticosteroid use for
mild persistent asthma treatment would increase
expenditures by over two billion dollars each year.
Results from IMPACT may assist in answering
this question.6 The National Asthma Education
and Prevention Program (NAEPP) will use the
results from IMPACT to update guidelines in
2006.
In IMPACT, 411 patients initially met the
criteria for mild persistent asthma, yet on further
screening, 64 patients were identified with higher
severity asthma and 30 patients had milder forms
of asthma. As Boushey et al discuss in their trial
publication, the lack of a difference in the
treatment groups may reflect the low rate of
asthma exacerbation.3 Only adults who were
nonsmokers with a long history of asthma and a
lower incidence of exacerbation were included.
The low percentage of eosinophils in sputum
(median range 0.4% to 0.6%) and the low nitric
oxide concentration in patient exhalations (median
range 16.4 to 16.8 parts per billion) may suggest
that the study population had a very mild form of
persistent asthma.7
Does as-needed use of inhaled corticosteroids
predispose mild persistent asthma patients to more
severe asthma and the progressive loss of lung
function? This question remains unanswered. No
randomized clinical studies have addressed
asthma outcomes when airway inflammation is
not suppressed on a daily basis.7
A recommendation for the use of as-needed
inhaled corticosteroids for patients with mild
persistent asthma must be considered carefully.
This as-needed inhaled corticosteroid use must be
supplemented with twice daily inhaled budesonide
or daily oral prednisone for a defined period as
done in the study. Furthermore, as-needed, quickrelief therapy with a beta agonist should be used
as defined in the NAEPP Guideline.2
As-needed corticosteroid therapy may be
effective in carefully selected patients who
understand the necessity for prompt treatment of
exacerbations with quick-relief, prescribed agents.
Assessment of the severity of asthma must be
carefully performed so as not to underestimate
patient needs. Advise patients to openly discuss
their level of asthma control and treatment needs.
More. . .
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Watch for further studies and the updated
NAEPP guidelines in 2006.
Users of this document are cautioned to use their own
professional judgment and consult any other necessary
or appropriate sources prior to making clinical
judgments based on the content of this document. Our
editors have researched the information with input
from experts, government agencies, and national
organizations. Information and Internet links in this
article were current as of the date of publication.
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